Veeva Sys Inc Stock Price, News & Analysis

Boehringer Ingelheim, a top 20 global biopharma company, has committed to implementing Veeva Vault CRM (NYSE: VEEV) as its commercial foundation. The company aims to launch up to 25 new treatments by 2030 and plans to expand on its existing Veeva Commercial Cloud solutions, One Medicine, and Amplify platforms. This decision builds upon their long-standing partnership where Veeva has served as their global CRM standard. The implementation is expected to help transform commercial operations, accelerate launch processes, and enable personalized customer engagement.

Veeva Systems' latest Pulse Field Trends Report reveals critical insights about healthcare professional (HCP) engagement in the biopharma industry. The report highlights that while in-person meetings with HCPs have declined by 7% compared to last year, synchronized engagement between sales and marketing can significantly improve outcomes. Currently, 65% of HCP engagements remain unsynchronized.

The data shows that coordinated approaches yield better results: rep meetings followed by digital exposure within 10 days are 30% more likely to result in prescriptions, digital ads after speaker programs increase prescription likelihood by 25%, and HCP website visits following rep meetings boost prescription probability by 60%.

Walgreens (Nasdaq: WBA) and Veeva Systems (NYSE: VEEV) have announced a long-term strategic partnership aimed at improving patient outcomes in the healthcare sector. The collaboration will enhance Veeva Data Cloud products while granting Walgreens access to Veeva's Data Cloud and Clinical Platform.

As a major retail and specialty pharmacy provider, Walgreens will contribute to expanding the breadth of data in Veeva Data Cloud, enabling life sciences companies to better understand market trends and improve patient care. This partnership leverages Walgreens' position as a neighborhood health destination and Veeva's expertise in life sciences software and data services.

Veeva Systems (NYSE: VEEV) has announced its upcoming virtual Investor Day scheduled for Thursday, November 7, 2024. The event will run from 1:30 p.m. to 3:30 p.m. PT (4:30 p.m. to 6:30 p.m. ET). Interested parties can attend the event by registering online through Veeva's investor relations website or via a direct link provided.

The company will broadcast the presentations live on its investor relations website, ir.veeva.com. For those unable to attend the live event, an archived webcast will be made available on the same platform after the event concludes.

This virtual Investor Day provides an opportunity for stakeholders to gain insights into Veeva Systems' performance, strategies, and future outlook directly from the company's leadership team.

Veeva Systems (NYSE: VEEV) announced that 18 of the top 20 medtech companies are using Veeva Development Cloud and Veeva Commercial Cloud applications to streamline processes across the total medtech product lifecycle. Over 125 customers are leveraging Veeva MedTech's expertise and technology from ideation to commercialization.

Veeva MedTech offers end-to-end product lifecycle management with Vault Clinical, Vault RIM, Vault Quality, and Vault Commercial applications. These solutions provide real-time insights, automate processes, and maintain inspection readiness, reducing manual work and improving cross-team collaboration.

The upcoming Veeva MedTech EU Summit in Amsterdam (Nov. 5-7) will feature industry leaders sharing insights and best practices.

Veeva Systems (NYSE: VEEV) has announced an expansion of Veeva Vault QMS, adding new capabilities for managing medtech field actions and product recalls. These features aim to improve oversight, timeliness, and accuracy throughout the field action process, from issue identification to closure.

The new capabilities are fully integrated into Vault QMS, connecting seamlessly with related quality processes such as complaint handling, quality risk management, CAPA, and change control. This integration reduces manual transcription needs and enhances efficiency.

Matt Roberts, senior director of quality systems at Teleflex, praised the collaboration with Veeva MedTech, stating that the new field actions capabilities will help streamline processes and better serve customers. Vishaka Rajaram, senior director of quality strategy at Veeva MedTech, emphasized the complex nature of field actions management and how Veeva Vault QMS addresses industry needs.

Veeva Systems (NYSE: VEEV) has announced a major release of Veeva Site Connect, enhancing clinical trial execution for sites and sponsors. The update includes new capabilities and a streamlined site-centric experience to simplify sponsor-site collaboration. Key features include:

1. Expanded functionality beyond document exchange and safety distribution
2. Optimized site user interface standardized across all trials
3. Open accessibility for all sites globally
4. Fixed-price implementation with 2-4 month setup

Seven of the top 20 biopharmas have already adopted Veeva Site Connect, aiming to reduce time and effort in site start-up, study conduct, and closeout. The platform is part of Veeva Clinical Platform, supporting patients, sites, and sponsors in streamlining clinical trials.

Veeva Systems (NYSE: VEEV) has announced its participation in the upcoming Citi 2024 Global TMT Conference in New York. Paul Shawah, EVP Strategy at Veeva, is scheduled to present on Wednesday, September 4, 2024, at 3:00 p.m. Eastern Time.

The presentation will be webcast live and archived for later viewing. Interested parties can access the webcast through Veeva's investor relations website at https://ir.veeva.com. This event provides an opportunity for investors and analysts to gain insights into Veeva's strategies and market position in the technology, media, and telecommunications sectors.

Veeva Systems (NYSE: VEEV) reported strong fiscal 2025 Q2 results, with total revenues of $676.2M, up 15% year-over-year, and subscription services revenues of $561.3M, up 19% year-over-year. The company's operating income increased 60% to $166.5M, while non-GAAP operating income rose 32% to $279.8M. Net income grew 53% to $171.0M, with non-GAAP net income up 35% to $267.3M.

Veeva highlighted key product advances, including the release of Vault CRM Service Center and enhancements to Veeva Site Connect. The company also provided guidance for Q3 FY2025, projecting total revenues between $682M and $685M, and updated its full-year FY2025 guidance to total revenues between $2,704M and $2,710M.